Pharmacokinetics of Cisplatin in Combined Cisplatin and 5-Fluorouracil Therapy: A Comparative Study of Three Different Schedules of Cisplatin Administration

Japanese Journal of Clinical Oncology

Volumn 28, Issue 3, 1998, Pages 168-175

  Ikeda, Kenichiro ^a   Terashima, Masanori ^a   Kawamura, Hidenobu ^a   Takiyama, Ikuo ^a   Koeda, Keisuke ^a   Takagane, Akinori ^a   Sato, Nobuhiro ^a   Ishida, Kaoru ^a   Iwaya, Takeshi ^a   Maesawa, Chihaya ^b   Yoshinari, Hiroko ^b   Saito, Kazuyoshi ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b Japan   (Japan)

Author keywords

5 fluorouracil; Cisplatin; Pharmacodynamics; Pharmacokinetics; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CF REGIMEN; CISPLATIN; FLUOROURACIL; PLATINUM;

AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECT; ESOPHAGUS TUMOR; FEMALE; HUMAN; KIDNEY; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; STOMACH TUMOR;

AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; KIDNEY; MALE; MIDDLE AGED; PLATINUM; STOMACH NEOPLASMS;

EID: 0032015824     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/28.3.168     Document Type: Article

References (29)

1. Ogawa M. Cisplatin in gastrointestinal tumors In: Kimura K, et al., editors. Cancer Chemotherapy: Challenges for the Future, Vol. 2. Tokyo: Excerpta Medica, 1987;308-13.
2. Ajani JA. Contribution of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol 1994;21:474-82.
3. Nobutoshi A, Ozawa S, Kitajima M, Iizuka T. Chemotherapy and multimodality therapy in the treatment of esophageal cancer. Gan To Kagaku Ryoho 1995;22:869-76 (in Japanese).
4. Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous. cell carcinoma of the esophagus: a Japanese esophageal oncology group trial. Jpn J Clin Oncol 1992;22:172-6.
5. Lacave AJ, Baron FJ, Anton LM, Estrada E, DeSande LMG, Palaccio I, et al Combination chemotherapy with cisplatin (CDDP) and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 1991;2:751-4.
6. Nishihira N, Abo S, Mori S, Isono K, Endo M, Iizuka T, et al Phase II study of CDDP for esophageal carcinoma. Gun To Kagaku Ryoho 1986;13:2939-16 (in Japanese).
7. Salem P, Hall SW, Benjamin RS, Murphy WK, Wharton JT, Bodey GP. Clinical phase I-II study of cis-dichlorodiammineplatinum(II) given by continuous iv infusion. Cancer Treat Rep 1978;62:1553-5.
8. Lokich JJ. Phase I study of in-dichlorodiammineplatinum(II) administered as a constant 5-day infusion Cancer Treat Rep 1980;64:905-8.
9. Posner MR, Ferrari L, Belliveau JF, Cummings FJ, Wiemann MC, O'Rourke A, et al. A phase I trial of continuous infusion cisplatin. Cancer 1987;59:15-18.
10. Saito Y, Mori K, Tominaga K, Yokoi K, Miyazawa N. Phase II study of 5-day continuous infusion of cis-dichlorodiammineplatinum(II) in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 1990;26:389-92.
11. Drewinko B, Brown BW, Gottlieb JA. The effect of cis-diamminedichloroplatinum(II) on cultured human lymphoma cells and its therapeutic implications. Cancer Res 1973;33:3091-5.
12. Bergerat JP, Barlogie B, Drewinko B. Effect of in-dichlorodiammineplatinum(II) on human colon carcinoma cells in vitro. Cancer Res 1979;39:1334-8.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
14. Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993;23:250-7.
15. Kurihara N, Kubota T, Hoshiya Y, Otani Y, Ando N, Kumai K, et al. Pharmacokinetics of cis-diamminedichloroplatinum(II) given as low-dose and high-dose infusions. J Surg Oncol 1996;62:135-8.
16. Schellens JH, Ma J. Planting AS, van-der-Burg ME, van-Meerten E, de-Boer-Dennert M, et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 1996;73:1569-75.
17. Desoize B, Marechal F, Millart H, Cattan A. Correlation of clinical pharmacokinetic parameters of cisplatin with efficacy and toxicity. Biomed Pharmacother 1991;45:203-7.
18. Evance WE, Crom WR, Abromotowitch M, Dodge R, Look AT, Bowman WP, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N Engl J Med 1986;314:471-7.
19. Reece PA, Stafford I, Russell J, Gill PG. Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin. J Clin Oncol 1986;4:1392-8.
20. Egorin MJ, Van Echo DA. Tipping SJ, Olman EA, Whitacre MY. Thompson BW, et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function Cancer Res 1984;44:5432-8.
21. Taguchi J, Saijo N, Miura K, Shinkai T, Eguchi K, Sasaki Y, et al. Prediction of hematologic toxicity of carboplatin by creatinine clearance rate. Jpn J Cancer Res 1987;78:977-82.
22. Sasaki Y, Fukuda M, Morita M, Shinkai T, Eguchi K, Tamura T, et al. Prediction from creatinine clearance of thrombocytopenia and recommended dose in patients receiving (glycolato-OO)diammineplatinum(II) (NSC 375101D). Jpn J Cancer Res 1990,81:196-200.
23. Reece PA, Stafford I, Russell J, Khan M. Gill PG. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 1987;5:304-9.
24. Hayashi K, Ide H, Shinoda M, Fukushima M. A phase II study of cisplatin and 5-fluorouracil plus leucovorin for squamous cell carcinoma of the esophagus. Cancer Res Thei Control 1993;3:115-19.
25. Ide H, Eguchi R, Nakamura T and Hayashi K. Effective combined injection method of fluoropyrimidine and platinum. Gan To Kagaku Ryoho 1996;23:1757-62 (in Japanese).
26. Koizumi W, Kurihara M, Sasai T, Yoshida S, Morise K, Imamura A, et al. A phase II study of combination therapy with 5-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer 1993;72:658-62.
27. O'Connell MJ, Moertel CG, Kvols LK, Hahn RG, Rubin J Clinical trial of cisplatin and intensive course 5-fluorouracil for the treatment of advanced colorectal cancer. Am J Clin Oncol 1986;9:192-5.
28. Terashima M, Ikeda K, Maesawa C, Kawamura H, Ishida K, Sato M, et al. Drug-sensitivity testing in patients with human oesophageal squamous cell carcinoma. Eur J Cancer 1992;28A:1347-50.
29. Kawamura H, Ikeda K, Takiyama I, Terashima M. The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer. Eur J Cancer 1997;33:960-6.